{"companyId":290652,"requestedLanguage":"en","resolvedLanguage":"en","availableLanguages":["en","fr","ja"],"companyName":"Poxel SA","headOfficeLocation":"Lyon, France","presidentName":null,"companySummary":null,"stockCode":"POXEL","currency":"EUR","capital":null,"sales":null,"employees":null,"employeesConsolidated":null,"humanCheck":false,"domains":["www.poxelpharma.com"],"businessContents":["clinical stage biopharmaceutical company","development of treatments for metabolic dysfunction-associated steatohepatitis (MASH)","development of treatments for rare disorders such as adrenoleukodystrophy (ALD) and autosomal domina","development of PXL065 (deuterium-stabilized R-pioglitazone)","development of PXL770 (direct AMPK activator)","development of TWYMEEG® (Imeglimin) for type 2 diabetes","strategic partnership with Sumitomo Pharma for Imeglimin in Japan"],"relations":[{"detailNumber":1,"relationCompanyName":"Sumitomo Pharma","relationCompanyId":null,"url":null,"linkUrl":null,"remarks":"候補複数(社名部分一致):20","lastCheckDate":"2026-10-14","raGroup":0,"raParent":0,"raChild":0,"raCustomer":50,"raSupplier":0,"raPartnership":0,"raFinance":0,"raInvest":0}],"dataSources":[{"detailNumber":1,"url":"https://www.poxelpharma.com/en_us/investors/company-information/profile","scoreAbout":101,"scoreBusiness":18,"scoreGroup":6,"scoreCustomer":3},{"detailNumber":2,"url":"https://www.poxelpharma.com/","scoreAbout":0,"scoreBusiness":66,"scoreGroup":47,"scoreCustomer":0},{"detailNumber":3,"url":"https://www.poxelpharma.com/fr","scoreAbout":0,"scoreBusiness":50,"scoreGroup":52,"scoreCustomer":52}]}